Details for Patent: 10,117,951

Which drugs does patent 10,117,951 protect, and when does it expire?

Patent 10,117,951 protects NOXAFIL and ZULRESSO and is included in two NDAs.

This patent has twenty-nine patent family members in thirteen countries.

Summary for Patent: 10,117,951

Title:	Sulfoalkyl ether cyclodextrin compositions
Abstract:	SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s):	Antle; Vincent D. (Olathe, KS)
Assignee:	CyDex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	14/954,772
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 10,117,951

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014	AP	RX	Yes	Yes			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 10,117,951

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603
Canada	2771879
China	101959508
China	105288650